Johns Hopkins HIV Guide
Rilpivirine
INDICATIONS
FDA
FDA
- Rilpivirine in combination with other ARVs is indicated for the treatment of HIV-1 infection in ART-naïve patients with HIV-1 RNA < 100,000 copies/mL.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: April 11, 2026
Citation
Auwaerter, Paul G, and Janessa M Smith. "Rilpivirine." Johns Hopkins HIV Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/6/Rilpivirine.
Auwaerter PG, Smith JM. Rilpivirine. Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/6/Rilpivirine. Accessed April 17, 2026.
Auwaerter, P. G., & Smith, J. M. (2026). Rilpivirine. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/6/Rilpivirine
Auwaerter PG, Smith JM. Rilpivirine [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2026. [cited 2026 April 17]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/6/Rilpivirine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rilpivirine
ID - 545229
A1 - Auwaerter,Paul,M.D.
AU - Smith,Janessa, PharmD, BCPS
Y1 - 2026/04/11/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/6/Rilpivirine
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
